CI Investments Inc. Reduces Holdings in AbbVie Inc. $ABBV

Posted by Brenda Bartman on Jul 23rd, 2026

CI Investments Inc. lowered its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 42.0% during the first quarter, Holdings Channel reports. The firm owned 123,910 shares of the company’s stock after selling 89,801 shares during the quarter. CI Investments Inc.’s holdings in AbbVie were worth $26,949,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Litman Gregory Wealth Management LLC acquired a new stake in AbbVie during the 4th quarter worth $28,000. Imprint Wealth LLC grew its holdings in AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after acquiring an additional 45 shares during the period. Westend Capital Management LLC purchased a new position in AbbVie in the fourth quarter valued at about $29,000. IFC & Insurance Marketing Inc. purchased a new stake in shares of AbbVie in the 4th quarter worth about $31,000. Finally, Legacy Wealth Managment LLC ID increased its stake in shares of AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after purchasing an additional 73 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

ABBV has been the topic of several analyst reports. Morgan Stanley raised their price target on shares of AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Piper Sandler reissued an “overweight” rating and issued a $298.00 price objective on shares of AbbVie in a research report on Tuesday, June 23rd. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a report on Monday, June 8th. Guggenheim raised their target price on AbbVie from $249.00 to $261.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. Finally, Wells Fargo & Company raised their price objective on AbbVie from $260.00 to $295.00 and gave the company an “overweight” rating in a research note on Friday, July 10th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $268.10.

Get Our Latest Analysis on AbbVie

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Canaccord Genuity raised its price target on AbbVie to $282 from $273 and reiterated a buy rating, signaling confidence in further upside for AbbVie Inc. (ABBV). Benzinga report
Positive Sentiment: AbbVie’s aesthetics business got a boost after Allergan Aesthetics received European Commission approval for Boey, expanding the company’s portfolio in Europe and potentially supporting future revenue growth. Yahoo Finance article
Neutral Sentiment: Several recent articles characterized AbbVie as a strong buy-and-hold name and noted that the stock has recently outperformed the broader market, reinforcing a generally constructive long-term view. Yahoo Finance article
Negative Sentiment: Investors are watching AbbVie’s Q2 oncology revenue closely, with analysts warning that weakness in Imbruvica may outweigh gains from Venclexta and newer cancer treatments, which could pressure results. Yahoo Finance article

AbbVie Trading Down 0.9%

Shares of ABBV opened at $253.75 on Thursday. The firm has a market cap of $448.32 billion, a price-to-earnings ratio of 125.00, a PEG ratio of 0.85 and a beta of 0.30. The stock has a 50 day moving average of $232.69 and a 200-day moving average of $222.41. AbbVie Inc. has a 52 week low of $186.77 and a 52 week high of $261.64.

AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.06. The firm had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same period last year, the business posted $2.46 earnings per share. On average, sell-side analysts predict that AbbVie Inc. will post 14.18 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio is currently 340.89%.

About AbbVie

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.